Gerald Novak

9.2k total citations
83 papers, 2.8k citations indexed

About

Gerald Novak is a scholar working on Psychiatry and Mental health, Physiology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Gerald Novak has authored 83 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Psychiatry and Mental health, 24 papers in Physiology and 22 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Gerald Novak's work include Dementia and Cognitive Impairment Research (28 papers), Alzheimer's disease research and treatments (22 papers) and Epilepsy research and treatment (22 papers). Gerald Novak is often cited by papers focused on Dementia and Cognitive Impairment Research (28 papers), Alzheimer's disease research and treatments (22 papers) and Epilepsy research and treatment (22 papers). Gerald Novak collaborates with scholars based in United States, Belgium and United Kingdom. Gerald Novak's co-authors include Herbert G. Vaughan, Walter Ritter, Max Wiznitzer, Joseph Maytal, Vaibhav A. Narayan, Simcha Pollack, Daniel Umbricht, Jeffrey A. Lieberman, Daniel C. Javitt and John M. Kane and has published in prestigious journals such as PLoS ONE, Neurology and PEDIATRICS.

In The Last Decade

Gerald Novak

79 papers receiving 2.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Gerald Novak United States	29	1.5k	1.1k	650	428	285	83	2.8k
Barbara A. Dworetzky United States	34	2.2k 1.5×	1.1k 1.0×	895 1.4×	235 0.5×	502 1.8×	123	3.4k
Sarah Archibald United States	25	659 0.5×	1.0k 1.0×	667 1.0×	416 1.0×	406 1.4×	39	3.4k
Johan Arends Netherlands	37	2.1k 1.4×	1.6k 1.5×	653 1.0×	192 0.4×	727 2.6×	99	3.4k
Sarah K. Madsen United States	28	907 0.6×	1.0k 1.0×	197 0.3×	637 1.5×	185 0.6×	53	2.6k
Katja Franke Germany	19	972 0.7×	1.6k 1.6×	525 0.8×	378 0.9×	65 0.2×	27	3.0k
Jeffrey R. Bishop United States	38	1.7k 1.2×	878 0.8×	461 0.7×	248 0.6×	379 1.3×	162	4.4k
Douglas Dean United States	32	486 0.3×	1.2k 1.1×	1.0k 1.6×	401 0.9×	172 0.6×	104	3.5k
Gregory L. Barkley United States	27	1.5k 1.0×	1.1k 1.0×	471 0.7×	156 0.4×	380 1.3×	60	2.5k
David Masur United States	22	2.3k 1.5×	683 0.6×	699 1.1×	878 2.1×	593 2.1×	36	3.4k
Allen E. Thornton Canada	29	1.1k 0.8×	755 0.7×	165 0.3×	310 0.7×	501 1.8×	94	3.2k

Countries citing papers authored by Gerald Novak

Since Specialization

Citations

This map shows the geographic impact of Gerald Novak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerald Novak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerald Novak more than expected).

Fields of papers citing papers by Gerald Novak

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerald Novak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerald Novak. The network helps show where Gerald Novak may publish in the future.

Co-authorship network of co-authors of Gerald Novak

This figure shows the co-authorship network connecting the top 25 collaborators of Gerald Novak. A scholar is included among the top collaborators of Gerald Novak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gerald Novak. Gerald Novak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kang, Sujin, Jamie Ford, Luc Bracoud, et al.. (2025). Prevalence and risk factors of cerebral microhemorrhages and superficial siderosis in cognitively unimpaired older adults: analysis from the CHARIOT‐PRO SubStudy. Alzheimer s & Dementia. 21(8). e70594–e70594.

Kang, Sujin, Susan Baker, Benedict Hayhoe, et al.. (2025). Organ-specific proteomic aging and cognitive performance: Implications for risk prediction of Alzheimer’s disease and related dementias in older adults. The Journal of Prevention of Alzheimer s Disease. 12(9). 100274–100274.

Grill, Joshua D., Rema Raman, Karin Ernström, et al.. (2024). Immediate Reactions to Alzheimer Biomarker Disclosure in Cognitively Unimpaired Individuals in a Global Truncated Randomized Trial. Neurology Clinical Practice. 14(2). e200265–e200265. 5 indexed citations

Zheng, Bang, Chinedu Udeh‐Momoh, Catherine Robb, et al.. (2022). Practice Effect of Repeated Cognitive Tests Among Older Adults: Associations With Brain Amyloid Pathology and Other Influencing Factors. Frontiers in Aging Neuroscience. 14. 909614–909614. 10 indexed citations

Papp, Kathryn V., Hany Rofael, Amy E. Veroff, et al.. (2022). Sensitivity of the Preclinical Alzheimer's Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer's Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial. The Journal of Prevention of Alzheimer s Disease. 9(2). 255–261. 17 indexed citations

Novak, Gerald, Johannes Streffer, Maarten Timmers, et al.. (2020). Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer’s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study. Alzheimer s Research & Therapy. 12(1). 73 indexed citations

Legdeur, Nienke, Maqsood Yaqub, Nina Beker, et al.. (2020). What Determines Cognitive Functioning in the Oldest-Old? The EMIF-AD 90+ Study. The Journals of Gerontology Series B. 76(8). 1499–1511. 18 indexed citations

Westwood, Sarah, Alison L. Baird, Sneha Anand, et al.. (2017). The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer’s pathology. Alzheimer s Research & Therapy. 9(1). 31–31. 29 indexed citations

Tang, Eugene, Stephanie L. Harrison, Linda Errington, et al.. (2015). Current Developments in Dementia Risk Prediction Modelling: An Updated Systematic Review. PLoS ONE. 10(9). e0136181–e0136181. 127 indexed citations

10.

Burnham, Samantha C., Nandini Raghavan, W.J. Wilson, et al.. (2015). Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer’s Disease Trials: An AIBL Study. Journal of Alzheimer s Disease. 46(4). 1079–1089. 26 indexed citations

11.

Burnham, Samantha C., Nandini Raghavan, Bill Wilson, et al.. (2014). P4‐293: COMPARISON OF THREE NORMATIVE DATA CORRECTION APPROACHES: A CROSS‐SECTIONAL EVALUATION IN THE AIBL STUDY. Alzheimer s & Dementia. 10(4S_Part_15). 4 indexed citations

12.

Liu, Enchi, Ajibade Ashaye, Karin Travers, et al.. (2014). P1‐147: A PROSPECTIVE, SYSTEMATIC LITERATURE REVIEW AND META‐ANALYSES TO EVALUATE GLOBAL AND REGIONAL BRAIN VOLUMES BY STRUCTURAL MRI AS BIOMARKERS OF ALZHEIMER'S DISEASE (AD) PROGRESSION. Alzheimer s & Dementia. 10(4S_Part_9).

13.

Samtani, Mahesh N., Nandini Raghavan, Gerald Novak, Partha Nandy, & Vaibhav A. Narayan. (2014). Disease progression model for Clinical Dementia Rating–Sum of Boxes in mild cognitive impairment and Alzheimer’s subjects from the Alzheimer’s Disease Neuroimaging Initiative. Neuropsychiatric Disease and Treatment. 10. 929–929. 46 indexed citations

14.

Yang, Eric, Michael Farnum, Victor S. Lobanov, et al.. (2011). Quantifying the Pathophysiological Timeline of Alzheimer's Disease. Journal of Alzheimer s Disease. 26(4). 745–753. 53 indexed citations

15.

Sperling, Michael R., Andrew Greenspan, Joyce A. Cramer, et al.. (2009). Carisbamate as adjunctive treatment of partial onset seizures in adults in two randomized, placebo‐controlled trials. Epilepsia. 51(3). 333–343. 39 indexed citations

16.

Zannikos, Peter, Gerald Novak, Caiping Yao, et al.. (2009). Pharmacokinetics of carisbamate (RWJ‐333369) in healthy Japanese and Western subjects. Epilepsia. 50(8). 1850–1859. 3 indexed citations

17.

French, Jacqueline A., Édouard Hirsch, J.P. Macher, et al.. (2007). Evaluation of carisbamate, a novel antiepileptic drug, in photosensitive patients: An exploratory, placebo-controlled study. Epilepsy Research. 74(2-3). 193–200. 28 indexed citations

18.

Novak, Gerald, Michael F. Kelley, Peter Zannikos, & Brian D. Klein. (2007). Carisbamate (RWJ-333369). Neurotherapeutics. 4(1). 106–109. 48 indexed citations

19.

Umbricht, Daniel, Daniel C. Javitt, Gerald Novak, et al.. (1999). Effects of risperidone on auditory event-related potentials in schizophrenia. The International Journal of Neuropsychopharmacology. 2(4). 299–304. 107 indexed citations

20.

Álvarez, Luis & Gerald Novak. (1985). Valproic acid in the treatment of Sydenham chorea. Pediatric Neurology. 1(5). 317–319. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact